Extended vs Intermittent Infusion of Meropenem with Colistimethate Sodium and Risk of Acute Kidney Injury in Critically Ill Patients: A Propensity Score-Matched Retrospective Cohort Study
Qiaoqiao Hu, Huajun Wang · 2026
Read Extended vs Intermittent Infusion of Meropenem with Colistimethate Sodium and Risk of Acute Kidney Injury in Critically Ill Patients: A Propensity Score-Matched Retrospective Cohort Study by Qiaoqiao Hu, Huajun Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13228856.txt.
Description
Qiaoqiao Hu and Huajun Wang compare a 2026 intensive-care question. Does dripping the antibiotic meropenem slowly over hours, rather than in quick doses, spare the kidneys of patients also receiving colistimethate, a last-resort drug notorious for kidney damage? Both medicines were treating carbapenem-resistant infections. Records from 2021 to 2025 were matched so the two infusion groups started alike, leaving 146 pairs.
Kidney injury struck about a quarter of the prolonged-infusion patients, against about forty percent with intermittent dosing. Severe injury stages were also less frequent with slow infusion. Because patients stayed on therapy for different lengths and some died meanwhile, the analysis used a competing-risk model. The authors present slow infusion as a simple kidney-sparing adjustment.
Catalog record
| CREATOR | Qiaoqiao Hu, Huajun Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |